Squadron Capital Management LLC 13F holdings
Squadron Capital Management LLC reported 34 positions with a total reported value of $292.1M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: RLMD RELMADA THERAPEUTICS INC (17.4%), CCCC C4 THERAPEUTICS INC (11.5%), COGT COGENT BIOSCIENCES INC (11.5%), KOD KODIAK SCIENCES INC (6.7%), RLAY RELAY THERAPEUTICS INC (6.2%). Against 2026-03-31 it opened 16 new positions and exited 12. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Squadron Capital Management LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 34 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| RLMD RELMADA THERAPEUTICS INC | 7,350,000 | $50.9M | 17.4% |
| CCCC C4 THERAPEUTICS INC | 7,200,000 | $33.6M | 11.5% |
| COGT COGENT BIOSCIENCES INC | 865,000 | $33.5M | 11.5% |
| KOD KODIAK SCIENCES INC | 500,000 | $19.5M | 6.7% |
| RLAY RELAY THERAPEUTICS INC | 970,000 | $18.1M | 6.2% |
| ZNTL ZENTALIS PHARMACEUTICALS INC | 3,700,000 | $17.9M | 6.1% |
| EWTX EDGEWISE THERAPEUTICS INC | 290,000 | $11.8M | 4.0% |
| MAZE MAZE THERAPEUTICS INC | 335,000 | $10.0M | 3.4% |
| IVA INVENTIVA SA | 2,435,000 | $9.2M | 3.2% |
| ANL ADLAI NORTYE LTD | 764,876 | $8.8M | 3.0% |
| ELVN ENLIVEN THERAPEUTICS INC | 160,000 | $8.1M | 2.8% |
| PALI PALISADE BIO INC | 3,000,000 | $6.3M | 2.1% |
| IKT INHIBIKASE THERAPEUTICS INC | 3,000,000 | $6.1M | 2.1% |
| ADAG ADAGENE INC | 1,250,000 | $5.2M | 1.8% |
| FBRX FORTE BIOSCIENCES INC | 225,000 | $4.8M | 1.6% |
| IFRX INFLARX NV | 2,000,000 | $4.5M | 1.5% |
| ASMB ASSEMBLY BIOSCIENCES INC | 160,000 | $4.4M | 1.5% |
| PMN PROMIS NEUROSCIENCES INC | 324,977 | $4.3M | 1.5% |
| CTNM CONTINEUM THERAPEUTICS INC | 260,000 | $4.3M | 1.5% |
| CMPS COMPASS PATHWAYS PLC | 300,000 | $4.2M | 1.5% |
| DFTX DEFINIUM THERAPEUTICS INC | 85,000 | $4.0M | 1.4% |
| SLGL SOL-GEL TECHNOLOGIES LTD | 52,000 | $3.9M | 1.3% |
| BIOA BIOAGE LABS INC | 155,000 | $3.8M | 1.3% |
| SCYX SCYNEXIS INC | 756,884 | $3.1M | 1.1% |
| PROQR THRAPEUTICS N V | 1,511,496 | $2.8M | 1.0% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 16 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| ELVN ENLIVEN THERAPEUTICS INC | 160,000 | $8.1M | 2.8% |
| ADAG ADAGENE INC | 1,250,000 | $5.2M | 1.8% |
| FBRX FORTE BIOSCIENCES INC | 225,000 | $4.8M | 1.6% |
| IFRX INFLARX NV | 2,000,000 | $4.5M | 1.5% |
| ASMB ASSEMBLY BIOSCIENCES INC | 160,000 | $4.4M | 1.5% |
| CTNM CONTINEUM THERAPEUTICS INC | 260,000 | $4.3M | 1.5% |
| CMPS COMPASS PATHWAYS PLC | 300,000 | $4.2M | 1.5% |
| DFTX DEFINIUM THERAPEUTICS INC | 85,000 | $4.0M | 1.4% |
| BIOA BIOAGE LABS INC | 155,000 | $3.8M | 1.3% |
| PROQR THRAPEUTICS N V | 1,511,496 | $2.8M | 1.0% |
| RZLT REZOLUTE INC | 403,410 | $2.1M | 0.7% |
| CUE CUE BIOPHARMA INC | 50,000 | $1.6M | 0.5% |
| CALC CALCIMEDICA INC | 1,244,864 | $1.3M | 0.4% |
| QUINCE THERAPEUTICS INC | 40,375 | $734.4K | 0.3% |
| INM INMED PHARMACEUTICALS INC | 325,000 | $503.8K | 0.2% |
| NMRA NEUMORA THERAPEUTICS INC. | 100,000 | $170.0K | <0.1% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 12 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| KALVISTA PHARMACEUTICALS INC | 985,100 | $19.8M | 7.9% |
| ABVX ABIVAX SA | 130,000 | $14.5M | 5.8% |
| NKTR NEKTAR THERAPEUTICS | 125,000 | $9.0M | 3.6% |
| EPRX EUPRAXIA PHARMACEUTICALS INC | 680,000 | $4.9M | 2.0% |
| GHRS GH RESEARCH PLC | 325,000 | $4.6M | 1.8% |
| ALXO ALX ONCOLOGY HLDGS INC | 1,460,000 | $2.9M | 1.2% |
| CNTX CONTEXT THERAPEUTICS INC | 1,100,000 | $2.9M | 1.2% |
| TRAW TRAWS PHARMA INC | 511,714 | $936.4K | 0.4% |
| TXMD THERAPEUTICSMD INC | 420,421 | $849.2K | 0.3% |
| SPRB SPRUCE BIOSCIENCES INC | 12,200 | $797.3K | 0.3% |
| HOWL WEREWOLF THERAPEUTICS INC | 563,535 | $469.2K | 0.2% |
| NEUP NEUPHORIA THERAPEUTICS INC | 76,728 | $312.3K | 0.1% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| CCCC C4 THERAPEUTICS INC | 2,250,000 | 7,200,000 | +220.0% | $33.6M |
| IVA INVENTIVA SA | 535,000 | 2,435,000 | +355.1% | $9.2M |
| RLAY RELAY THERAPEUTICS INC | 672,500 | 970,000 | +44.2% | $18.1M |
| KOD KODIAK SCIENCES INC | 380,000 | 500,000 | +31.6% | $19.5M |
| COGT COGENT BIOSCIENCES INC | 787,492 | 865,000 | +9.8% | $33.5M |
| MAZE MAZE THERAPEUTICS INC | 257,500 | 335,000 | +30.1% | $10.0M |
| SLGL SOL-GEL TECHNOLOGIES LTD | 31,000 | 52,000 | +67.7% | $3.9M |
| LPCN LIPOCINE INC NEW | 450,000 | 810,000 | +80.0% | $2.1M |
| ZNTL ZENTALIS PHARMACEUTICALS INC | 3,631,000 | 3,700,000 | +1.9% | $17.9M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| SCYX SCYNEXIS INC | 7,608,695 | 756,884 | -90.1% | $3.1M |
| RLMD RELMADA THERAPEUTICS INC | 8,474,571 | 7,350,000 | -13.3% | $50.9M |
| ANL ADLAI NORTYE LTD | 1,265,231 | 764,876 | -39.5% | $8.8M |
| EWTX EDGEWISE THERAPEUTICS INC | 350,000 | 290,000 | -17.1% | $11.8M |
| IKT INHIBIKASE THERAPEUTICS INC | 3,500,000 | 3,000,000 | -14.3% | $6.1M |
| KTTA PASITHEA THERAPEUTICS CORP | 2,100,000 | 1,000,000 | -52.4% | $515.4K |
| NXTC NEXTCURE INC | 265,000 | 64,464 | -75.7% | $103.1K |
CIK 2050709 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
